@article{6458026450324fd3b8ee4e29a376293b,
title = "Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations",
abstract = "The Canadian Multiple Sclerosis Working Group has updated its treatment optimization recommendations (TORs) on the optimal use of disease-modifying therapies for patients with all forms of multiple sclerosis (MS). Recommendations provide guidance on initiating effective treatment early in the course of disease, monitoring response to therapy, and modifying or switching therapies to optimize disease control. The current TORs also address the treatment of pediatric MS, progressive MS and the identification and treatment of aggressive forms of the disease. Newer therapies offer improved efficacy, but also have potential safety concerns that must be adequately balanced, notably when treatment sequencing is considered. There are added discussions regarding the management of pregnancy, the future potential of biomarkers and consideration as to when it may be prudent to stop therapy. These TORs are meant to be used and interpreted by all neurologists with a special interest in the management of MS.",
keywords = "MULTIPLE SCLEROSIS, Recommendations, Sequencing, THERAPEUTICS, Treatment optimization",
author = "Freedman, {Mark S.} and Virginia Devonshire and Pierre Duquette and Giacomini, {Paul S.} and Fabrizio Giuliani and Levin, {Michael C.} and Xavier Montalban and Morrow, {Sarah A.} and Jiwon Oh and Dalia Rotstein and Yeh, {E. Ann}",
note = "Funding Information: E. Ann Yeh has received grants from Biogen, the National MS Society, the Consortium of MS Centers, the Multiple Sclerosis Society of Canada, the Ontario Institute for Regenerative Medicine, SCN, the Sick Kids Foundation, CBMH, Teva and the Guthy Jackson Foundation; and honoraria from ACI, the US FDA, and Juno. Funding Information: Sarah A. Morrow has received grants from the Multiple Sclerosis Society of Canada and CIHR; has acted as site principal investigator for studies with Novartis, Roche, and EMD Serono; and has received research funds for investigator-initiated studies from Hoffmann La Roche, Biogen, Sanofi Genzyme, and EMD Serono. Funding Information: The Canadian Treatment Optimization Recommendations was a project of the Canadian MS Working Group (CMSWG) under the aegis of the Canadian Network of MS Clinics. All of the authors have reviewed the final version of this manuscript and have agreed with the recommendations. CMSWG members received no remuneration for their development of the recommendations or the accompanying manuscript. Participants were reimbursed for costs associated with attending the June 2019 meeting. Funding was provided by the Canadian Network of MS Clinics through unrestricted grants obtained from EMD Serono, Roche, Biogen, Sanofi-Genzyme, Teva, and Pendopharm. Corporate donors had no involvement in CMSWG discussions, in the development of the recommendations or in the review of the manuscript. The CMSWG acknowledges the assistance of Anne St-Michel and Steven Manners of Communications Lansdowne for logistics and editorial development, with funding through grants obtained by the Canadian Network of MS Clinics. Publisher Copyright: Copyright {\textcopyright} 2020 The Canadian Journal of Neurological Sciences Inc..",
year = "2020",
month = jul,
day = "1",
doi = "10.1017/cjn.2020.66",
language = "English (US)",
volume = "47",
pages = "437--455",
journal = "Canadian Journal of Neurological Sciences",
issn = "0317-1671",
publisher = "Canadian Journal of Neurological Sciences",
number = "4",
}